The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour

Colorectal Disease

Volumn 13, Issue 10, 2011, Pages 1110-1115

  Machlenkin, S ^a   Pinsk, I ^a   Tulchinsky, H ^b   Ziv, Y ^c   Sayfan, J ^d   Duek, D ^e   Rabau, M ^b   Walfisch, S ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d HAEMEK MEDICAL CENTER   (Israel)

^e RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Gastrointestinal stromal tumour; Imatinib; Neoadjuvant; Rectum

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CLINICAL ARTICLE; DRUG ERUPTION; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; ISRAEL; MALE; MEDICAL RECORD REVIEW; MITOSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECTAL GASTROINTESTINAL STROMAL TUMOR; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES; RECTAL NEOPLASMS; SURVIVAL RATE;

EID: 80053088369     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2010.02442.x     Document Type: Article

References (27)

1. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1, 458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100: 162-8.
2. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25: 1121-33.
3. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7.
4. Antonescu CR, Viale A, Sarran L et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004; 10: 3282-90.
5. Wasag B, Debiec-Rychter M, Pauwels P et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol 2004; 17: 889-94.
6. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41-7.
7. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.
8. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117(KIT). Mod Pathol 2000; 13: 1134-42.
9. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
10. Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt D. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathologic study. Hum Pathol 1998; 29: 791-800.
11. Casper ES. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2000; 1: 267-73.
12. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
13. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-12.
14. Blay JY, Bonvalot S, Casali P et al., GIST consensus meeting panelists Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-78.
15. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
16. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-31.
17. Mandalà M, Pezzica E, Tamborini E et al. Neoadjuvant Imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome. Eur J Gastroenterol Hepatol 2007; 19: 711-3.
18. Ebihara Y, Okushiba S, Kawarada Y, Kitashiro S, Katoh H, Kondo S. Neoadjuvant Imatinib in a gastrointestinal stromal tumor of the rectum: report of a case. Surg Today 2008; 38: 174-7.
19. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the pre-Imatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103: 821-9.
20. Dong C, Jun-Hui C, Xiao-Jun Y et al. Gastrointestinal stromal tumors of the rectum: clinical, pathologic, immunohistochemical characteristics and prognostic analysis. Scand J Gastroenterol 2007; 42: 1221-9.
21. Miettinen M, El Rifai W, Sobin HL, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-83.
22. Sturgeon C, Chejfec G, Espat NJ. Gastrointestinal stromal tumors: a spectrum of disease. Surg Oncol 2003; 12: 21-6.
23. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose Imatinib: randomised trial. Lancet 2004; 364: 1127-34.
24. Shibata Y, Ueda T, Seki H, Yagihashi N. Gastrointestinal stromal tumour of the rectum. Eur J Gastroenterol Hepatol 2001; 13: 283-6.
25. Changchien CR, Wu MC, Tasi WS et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum 2004; 47: 1922-9.
26. Tsai MC, Lin JW, Lin SE, Chen HH, Lee CM, Hu TH. Prognostic analysis of rectal stromal tumors by reference of National Institutes of Health risk categories and immunohistochemical studies. Dis Colon Rectum 2008; 51: 1535-43.
27. Eisenberg BL, Harris J, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant Imatinib Mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST) - early results of RTOG 0132. J Surg Oncol 2009; 99: 42-7.